Main menu

Workpackages - Overview and Objectives

 


 




Title

Start
Month

End
Month

 

WP1

Day to day management of the consortium.

1

60

 

WP2

Protocols for patient inclusion and for handling of samples and development of standard operation procedure (SOP) for handling of samples in the laboratory and the analytical procedures.

1

6

 

WP3

Collection of tumor, blood and urine samples from patients with bladder cancer in Denmark, Sweden, Holland and Spain.

7

36

 

WP4

Collection of tumor, blood and urine samples from patients with bladder cancer in Denmark, Sweden, Holland and Spain .

1

16

 

WP5

Transfer of microarray based gene signature to QPCR platform and microarray and QPCR based classification of samples.

1

12, 48

 

WP6

Validate microRNA signatures for prediction of the outcome in bladder cancer.

1

48

 

WP7

Analyse SNP´s in inflammatory genes associated with risk of disease progression.

1

48

 

WP8

Validation of urinary markers for diagnosis of recurrent UCC and development of a decision model for surveilance in which DNA tests replace cystoscopies.

1

24, 48

 

WP9

Modelling the disease process: develop algorithms that weight the individual clinical and molecular parameters and provide continuous risk scores with clearly interpretable end-points such as risk of progression or risk of recurrence.

1

30

 

WP10

Apply developed nomograms risk assessment on all patients included and compare to clinical outcome and develop software for clinical implementation of nomograms.

48

60

 

WP11

Dissemination/exploitation.

 

60

 


 

WP1

Management

To reach project targets according to project plan while keeping timelines, budgets, resources and quality planned. Management of communication among partners, coordination and control of all project activities.
Chairing of the steering committee.
Management of deviations, contingency planning.
Quality assurance of deliverables.
Communication with the Commission.

WP2

Protocols for patient inclusion and for handling of samples and development of standard operation procedure (SOP) for handling of samples in the laboratory and the analytical procedures.

Develop protocols for patient inclusion in the study and for sample handling in clinical settings in order to secure optimal quality of collected material.
Develop standard operation procedures (SOP) for handling of samples in the laboratory and for the analytical procedures.
Develop software for registration of clinical follow-up information.

WP3

Collection of tumor, blood and urine samples from patients with bladder cancer in Denmark, Sweden, Holland and Spain

To collect the disired number of samples and associated follow-up information for the study.

WP4

Analyse biological differences in synchronous and metachronous bladder tumors

To analyze if multiple tumors from single visits (synchronous tumors) and tumors from several subsequent visits (metachronous tumors) show different molecular classifications (88 gene progression signature and show changes in biological properties and molecular pathways analyzed by Affymetrix SNP and Expression arrays.

WP5

Transfer of microarray based gene signature to QPCR platform and microarray and QPCR based classification of samples

To transfer the microarray based gene signature to QPCR platform for easier clinical utility.
To make a molecular prognosis classification of tumors collected (the actual number of tumors classified from individual patients depend on results from WP5) using the custom microarray based method, as well as the qRT-PCR method.

WP6

Validate microRNA signatures for prediction of the outcome in bladder cancer

To validate if already identified miRNA molecules that correlate with clinical outcome add additional predictive value to constructed nomograms.

WP7

Analyse SNP´s in inflammatory genes associated with risk of disease progression

To validate SNP´s in inflammatory genes in prospectively collected bladder tumors using SNPlex platform

WP8

Validation of urinary markers for diagnosis of recurrent UCC and development of a decision model for surveilance in which DNA tests replace cystoscopies.

Identify, evaluate and validate biomarkers (microsatellites, FGFR3 and PIK3CA mutation status, and promoter methylation) for early detection/monitoring of recurrent UCC as well as for prognosis prediction and treatment selection. Based on the results a decision model will be build that allows urologists and pathologists to stratify patients with noninvasive UCC for follow-up regimes.

WP9

Modelling the disease process: develop algorithms that weight the individual clinical and molecular parameters and provide continuous risk scores with clearly interpretable end-points such as risk of progression or risk of recurrence

To obtain predictive survival models for the risk of tumor progression and recurrence for non-invasive bladder cancer.

WP10

Apply developed nomograms risk assessment on all patients included and compare to clinical outcome and develop software for clinical implementation of nomograms

To apply developed molecular and clinical risk based nomograms on all patient visits and compare to clinical outcome.
To develop a software solution for implementation of risk assessment into the clinical settings and guidelines for use.

WP11

Dissemination/exploitation

To IP-protect the developed nomogram algorithms.
To write scientific papers describing the results of the work.